Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barre syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of (a) an S1P receptor agonist, and (b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.本發明揭示了包含至少一種S1P受體促效劑之醫藥組合，以及一種用於治療脫髓鞘疾病(例如與其相關聯之多發性硬化症或病症或格-巴二氏徵候群)之方法，其包含共同投予(例如同時或依次)有效治療量之a) S1P受體促效劑，及b)對至少一種脫髓鞘疾病症狀顯示臨床活性之至少一種活性助劑(co-agent)。
